The future R&D landscape in non-alcoholic steatohepatitis (NASH).
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
03
07
2018
revised:
06
09
2018
accepted:
27
09
2018
pubmed:
7
10
2018
medline:
1
8
2019
entrez:
7
10
2018
Statut:
ppublish
Résumé
Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue for the 21st century and is associated with significant liver-related morbidity and mortality. At present, there are no approved drug therapies for NASH. Consequently, NASH has become the focus of significant public and private research and development. In this review, we highlight the research and development (R&D) challenges and opportunities in this emerging therapeutic area. In particular, we consider the impact of the development of new biomarker strategies on clinical trial execution and design, and the positioning of single and combination therapies in future approaches to the treatment of NASH.
Identifiants
pubmed: 30291900
pii: S1359-6446(18)30119-3
doi: 10.1016/j.drudis.2018.09.020
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Pagination
560-566Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.